VOR · Vor Biopharma Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $321.53M | $93.31M | $94.31M | $64.55M | $31.62M |
| SG&A | $50.11M | $27.88M | $31.72M | $28.87M | $11.75M |
| Total Operating Expenses | $371.64M | $121.19M | $126.04M | $93.42M | $43.37M |
| D&A | $2.89M | $3.53M | $3.49M | $2.52M | $605.0K |
| Operating Income | ($371.64M) | ($121.19M) | ($126.04M) | ($93.42M) | ($43.37M) |
| Interest Expense | - | - | - | - | - |
| Income Tax | - | - | - | - | - |
| Net Income | ($695.98M) | ($116.91M) | ($117.86M) | ($92.09M) | ($43.34M) |
| EPS - Basic | ($70.50) | ($34.00) | ($35.00) | ($46.60) | - |
| EPS - Diluted | ($70.50) | ($34.00) | ($35.00) | ($46.60) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $396.49M | $81.95M | $31.36M | $57.71M | $119.80M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $5.13M | $1.50M | $815.0K | $1.77M | $1.54M |
| Current Assets | $458.11M | $96.51M | $140.80M | $236.95M | $214.40M |
| Total Assets | $464.13M | $142.89M | $198.13M | $299.37M | $242.59M |
| Current Liabilities | $25.17M | $18.61M | $15.57M | $13.12M | $10.15M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $628.44M | $46.23M | $47.40M | $48.76M | $26.33M |
| Stockholders' Equity | ($164.31M) | $96.66M | $150.72M | $250.61M | $216.26M |
| Retained Earnings | ($1.15B) | ($456.99M) | ($340.08M) | ($222.22M) | ($130.12M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($142.71M) | ($99.66M) | ($100.29M) | ($85.14M) | ($36.29M) |
| Investing Cash Flow | ($48.80M) | $96.86M | $71.01M | ($94.09M) | ($4.16M) |
| Financing Cash Flow | $503.81M | $53.39M | $2.94M | $117.14M | $82.53M |
| CapEx | $941.0K | $229.0K | $1.07M | $8.46M | $4.16M |
| Free Cash Flow | ($143.65M) | ($99.89M) | ($101.36M) | ($93.61M) | ($40.45M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | 0.21 | 0.85 | 0.86 | 1.02 | 0.93 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -150.0% | -81.8% | -59.5% | -30.8% | -17.9% |
| Return on equity | 423.6% | -120.9% | -78.2% | -36.7% | -20.0% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 |
| Quick ratio | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 |
| Cash ratio | 15.75 | 4.40 | 2.01 | 4.40 | 11.80 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | -2.82 | 1.48 | 1.31 | 1.19 | 1.12 |
| Liabilities / Assets | 1.35 | 0.32 | 0.24 | 0.16 | 0.11 |
| Efficiency | |||||
| Asset turnover | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | 15.8x | 20.1x | 17.7x | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -206.7% | 3.8% | -34.9% | -115.4% | - |
| Net income growth (YoY) | -495.3% | 0.8% | -28.0% | -112.5% | - |
| EPS growth (YoY) | -107.4% | 2.9% | 24.9% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -43.8% | 1.5% | -8.3% | -131.4% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | - | -35.9% | -39.9% | 15.9% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Vor Biopharma Inc. against the 5 most active filers in the same SIC group.